Friday, December 30, 2011


Used for thousands of years for everything, everyone knows that. But what about the research part of it? Marijuana Research History - When did the first case studies of medical cannabis begin and what were these studies?

The La Guardia Committee Report (1944)

Physical, Mental, and Moral Effects of Marijuana: The Indian Hemp Drugs Commission Report (1894)


The British Pharmaceutical Codex  (1934)
New Remedies:Pharmaceutically and Therapeutically Considered Fourth Edition (1843)
On the Haschisch or Cannabis Indica (1857)
The Physiological Activity of Cannabis Sativa (1913)

CANNABIS, U.S.P. (American Cannabis Extract) (1929)
History of Cannabis and Its Preparations in Saga, Science and Sobriquet (2007)
Observations on the medicinal properties of the Cannabis Sativa of India (1843)
Cannabis Sativa Seu Indica: Indian Hemp (1895)
Collapse after intravenous injection of hashish. (1968)
Adverse Effects of Intravenous Cannabis Tea (1977)
Paraquat and marijuana: epidemiologic risk assessment. (1978)
Hashish and drug abuse in Egypt during the 19th and 20th centuries
Marihuana and drug abuse. Recommendations of the Committee on Public Health, New York Academy of Medicine. (1973)
Observations on the Cannabis Indica, or Indian Hemp (1843)
A Case of Dysmenorrh a in Which the Tincture of Cannabis Indica Was Employed, with Some Observations upon That Drug (1847)

Phytochemical and genetic analyses of ancient cannabis from Central Asia (700 BC)
Cannabinoid pharmacology: the first 66 years (2006)

Observations on the raising and dressing of hemp (1789)
Medicinal use of cannabis in the United States: Historical perspectives, current trends, and future directions (2009)

American Medical Association Opposes the Marijuana Tax Act of 1937
On the Action of Cannabis Indica (1883)

Friday, December 16, 2011

From Medscape General Medicine

It Is Time for Marijuana to Be Reclassified - Cannabis Research A-Z
 George Lundberg, MD, comments on why marijuana should be reclassified as something other than a Schedule I drug. From Medscape General Medicine

Thursday, December 15, 2011

BREAST CANCER - Univesity Study

Suppression of Nerve Growth Factor Trk Receptors and Prolactin Receptors by Endocannabinoids Leads to Inhibition of Human Breast and Prostate Cancer Cell Proliferation

Copyright © 2000 by The Endocrine Society
  Dominique Melck, Luciano De Petrocellis, Pierangelo Orlando, Tiziana Bisogno, Chiara Laezza, Maurizio Bifulco and Vincenzo Di Marzo
Istituto per la Chimica di Molecole di Interesse Biologico (D.M., T.B., V.D.M.), Istituto di Cibernetica (L.D.P.), and Istituto di Biochimica delle Proteine ed Enzimologia (P.O.), Consiglio Nazionale delle Ricerche, 80072 Arco Felice (NA); and Centro di Endocrinologia e Oncologia Sperimentale, Consiglio Nazionale delle Ricerche, and Dipartimento di Biologia e Patologia Cellulare e Molecolare, Università di Napoli Federico II (C.L., M.B.), 80131 Naples, Italy
Address all correspondence and requests for reprints to: Dr. Vincenzo Di Marzo, Istituto per la Chimica di Molecole di Interesse Biologico, Consiglio Nazionale delle Ricerche, 80072 Arco Felice (NA), Italy. E-mail:

Anandamide and 2-arachidonoylglycerol (2-AG), two endogenous ligands of the CB1 and CB2 cannabinoid receptor subtypes, inhibit the proliferation of PRL-responsive human breast cancer cells (HBCCs) through down-regulation of the long form of the PRL receptor (PRLr). Here we report that 1) anandamide and 2-AG inhibit the nerve growth factor (NGF)-induced proliferation of HBCCs through suppression of the levels of NGF Trk receptors; 2) inhibition of PRLr levels results in inhibition of the proliferation of other PRL-responsive cells, the prostate cancer DU-145 cell line; and 3) CB1-like cannabinoid receptors are expressed in HBCCs and DU-145 cells and mediate the inhibition of cell proliferation and Trk/PRLr expression. ß-NGF-induced HBCC proliferation was potently inhibited (IC50 = 50–600 nM) by the synthetic cannabinoid HU-210, 2-AG, anandamide, and its metabolically stable analogs, but not by the anandamide congener, palmitoylethanolamide, or the selective agonist of CB2 cannabinoid receptors, BML-190. The effect of anandamide was blocked by the CB1 receptor antagonist, SR141716A, but not by the CB2 receptor antagonist, SR144528. Anandamide and HU-210 exerted a strong inhibition of the levels of NGF Trk receptors as detected by Western immunoblotting; this effect was reversed by SR141716A. When induced by exogenous PRL, the proliferation of prostate DU-145 cells was potently inhibited (IC50 = 100–300 nM) by anandamide, 2-AG, and HU-210. Anandamide also down-regulated the levels of PRLr in DU-145 cells. SR141716A attenuated these two effects of anandamide. HBCCs and DU-145 cells were shown to contain 1) transcripts for CB1 and, to a lesser extent, CB2 cannabinoid receptors, 2) specific binding sites for [3H]SR141716A that could be displaced by anandamide, and 3) a CB1 receptor-immunoreactive protein. These findings suggest that endogenous cannabinoids and CB1 receptor agonists are potential negative effectors of PRL- and NGF-induced biological responses, at least in some cancer cells.

read More Studies

War on drugs scam - Cannabis Research A-Z

Since the drug war has become so unpopular with the electorate, instead of politicians actually changing the drug laws, the Department of Defense seeks to reduce and conceal the real costs by transferring the "dirty work" to private contractors to do what "U.S. military forces are not allowed or not encouraged to do." ~ Eric Blair 

The BBC (in Spanish) is reporting that the U.S. Department of Defense is delegating the war on drugs to private mercenary companies.

Video - Radio Host Alex Jones Addresses The Scam
Of those companies, the increasingly infamous organization previously known as Blackwater is said to have received several multimillion-dollar government contracts for "providing advice, training and conducting operations in drug producing countries and those with links to so-called "narco-terrorism" including Latin America."

The "no bid" contracts, issued under the Counter-Narcoterrorism Technology Program Office's $15 billion dollar budget, are described as "non-specific" and are said to be "juicy" for the private contractors. The Pentagon says "the details of each cost in very general contracts do not go through bidding processes."

An unnamed analyst says "the responsibility of the public and national security changing from a state's duty to be a private business...has become the trend of the future."

Although parts of the drug war have been privatized for years, the BBC reports this "transfer" of responsibilities is an attempt to placate those looking for Pentagon budget cuts in an election year.
According to Larry Birns, director of the Council on Hemispheric Affairs (COHA), "the drug war is unpopular and has no political weight except in an election year like this, so the Department of Defense wants to remove that spending from their accounts."

"They surreptitiously want to reduce anti-drug budget by transferring it to private agencies," said Birns.

Bruce Bagley, head of International Studies at the University of Miami, agrees with Birns that the main reason for privatizing the drug war is to sidestep "the high political cost."

But this move is not without risk, as private mercenaries have known to operate outside of national and international laws.  "Here we go into a vague area where the rules of engagement are not clear and there is almost zero accountability to the public or the electorate," said Bagley.
The Pentagon maintains that it's perfectly legal, and mercenaries must follow strict parameters. However, Bagley points out that "few members of the Oversight Committees of the Senate and the House are aware, but they are required to keep secret, so all this flies under the radar."

There are concerns that contractors acting independently will threaten the sovereignty of the "key countries" in which they will operate.  The Pentagon says the largest efforts will occur in Latin America including Mexico, Central America, Caribbean, Colombia and other Andean countries.

Professor Bagley says these private armies could "generate a nationalist backlash if the public came to realize the situation" of operations in their countries.

Once again, the war on drugs creates the opportunity to place troops in countries where having American soldiers would be politically disadvantageous, or simply impossible.

Ultimately, the Pentagon claims they will save money because private contractors don't have the bureaucracy and hierarchy involved in operations and because "if any of its employees dies, they are responsible."

Apparently, humanity is the last concern for the Pentagon budget, which always seems to have plenty of money for advanced weapons systems (also privatized), but is consistently lacking in benefits for its veterans.
By privatizing the drug war, they no longer have to concern themselves with paying for benefits for warriors who pledge allegiance to the United States and take an oath to defend its Constitution.

As the war on drugs is increasingly viewed as a money-draining failure, it's unlikely that this move to privatize it will succeed in anything but creating demand for more government allocated profit, thus fueling its continuance through corporate lobbying to prevent a political end to such lunacy.

Source; Eric Blair - Know the lies

Friday, December 9, 2011

Cannabis Reduces Skin Cancer

Inhibition of skin tumor growth and angiogenesis
in vivo by activation of cannabinoid receptors

Nonmelanoma skin cancer is one of the most common malignancies in humans. Different therapeutic strategies for the treatment of these tumors are currently being investigated. Given the growth-inhibiting effects of cannabinoids on gliomas and the wide tissue distribution of the two subtypes of cannabinoid receptors (CB1 and CB2), we studied the potential utility of these compounds in anti–skin tumor therapy. Here we show that the CB1 and the CB2 receptor are expressed in normal skin and skin tumors of mice and humans.

In cell culture experiments pharmacological activation of cannabinoid receptors induced the apoptotic death of tumorigenic epidermal cells, whereas the viability of nontransformed epidermal cells remained unaffected. Local administration of the mixed CB1/CB2 agonist WIN-55,212-2 or the selective CB2 agonist JWH-133 induced a considerable growth inhibition of malignant tumors generated by inoculation of epidermal tumor cells into nude mice.

Cannabinoid-treated tumors showed an increased number of apoptotic cells. This was accompanied by impairment of tumor vascularization, as determined by altered blood vessel morphology and decreased expression of proangiogenic factors (VEGF, placental growth factor, and angiopoietin 2). Abrogation of EGF-R function was also observed in cannabinoid-treated tumors. These results support a new therapeutic approach for the treatment of skin tumors.

read entire study